KLRS Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Kalaris Therapeutics, Inc.'s net margin of --. Kalaris Therapeutics, Inc.'s return on equity of -65.74% beat CEL-SCI Corp.'s return on equity of -230.36%.

Kalaris Therapeutics, Inc. has a consensus price target of $19.67, signalling upside risk potential of 133.02%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 707.99%. Given that CEL-SCI Corp. has higher upside potential than Kalaris Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc. has a beta of -0.088, which suggesting that the stock is 108.819% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.

Kalaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kalaris Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Kalaris Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Kalaris Therapeutics, Inc.'s net income of -$11.9M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Kalaris Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kalaris Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Kalaris Therapeutics, Inc.'s net margin of -953.4%. Kalaris Therapeutics, Inc.'s return on equity of -65.74% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Kalaris Therapeutics, Inc. has a consensus price target of $19.67, signalling upside risk potential of 133.02%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1277.04%. Given that IGC Pharma, Inc. has higher upside potential than Kalaris Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc. has a beta of -0.088, which suggesting that the stock is 108.819% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.78%.

Kalaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kalaris Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Kalaris Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Kalaris Therapeutics, Inc.'s net income of -$11.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Kalaris Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kalaris Therapeutics, Inc. is -- versus 21.12x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Kalaris Therapeutics, Inc.'s net margin of -255.85%. Kalaris Therapeutics, Inc.'s return on equity of -65.74% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Kalaris Therapeutics, Inc. has a consensus price target of $19.67, signalling upside risk potential of 133.02%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that Kalaris Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Kalaris Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Kalaris Therapeutics, Inc. has a beta of -0.088, which suggesting that the stock is 108.819% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Kalaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Kalaris Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kalaris Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Kalaris Therapeutics, Inc.'s net income of -$11.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Kalaris Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kalaris Therapeutics, Inc. is -- versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to Kalaris Therapeutics, Inc.'s net margin of 13.19%. Kalaris Therapeutics, Inc.'s return on equity of -65.74% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Kalaris Therapeutics, Inc. has a consensus price target of $19.67, signalling upside risk potential of 133.02%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 511.11%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Kalaris Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc. has a beta of -0.088, which suggesting that the stock is 108.819% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Kalaris Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kalaris Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Kalaris Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Kalaris Therapeutics, Inc.'s net income of -$11.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Kalaris Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kalaris Therapeutics, Inc. is -- versus 2.29x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.